Docosahexaenoic acid stimulates non-amyloidogenic APP processing resulting in reduced Aβ levels in cellular models of Alzheimer's disease
Version of Record online: 15 AUG 2007
European Journal of Neuroscience
Volume 26, Issue 4, pages 882–889, August 2007
How to Cite
Sahlin, C., Pettersson, F. E., Nilsson, L. N. G., Lannfelt, L. and Johansson, A.-S. (2007), Docosahexaenoic acid stimulates non-amyloidogenic APP processing resulting in reduced Aβ levels in cellular models of Alzheimer's disease. European Journal of Neuroscience, 26: 882–889. doi: 10.1111/j.1460-9568.2007.05719.x
- Issue online: 15 AUG 2007
- Version of Record online: 15 AUG 2007
- Received 5 March 2007, revised 15 May 2007, accepted 28 June 2007
Table S1. Total cholesterol levels in APPSwe and APPArc-Swe stably transfected SH-SY5Y cells after 11 days of treatment with 100 μM DHA or DMSO vehicle. Fig. S1. Protein levels of neprilysin are unaffected by docosahexaenoic acid (DHA). Fig. S2. Levels of Aβ38 and Aβ40 in culture media from cells treated with docosahexaenoic acid (DHA).
|EJN_5719_sm_FigS1.doc||283K||Supporting info item|
|EJN_5719_sm_FigS2.doc||2780K||Supporting info item|
|EJN_5719_sm_TableS1.doc||25K||Supporting info item|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.